Welcome to our dedicated page for Atai Beckley news (Ticker: ATAI), a resource for investors and traders seeking the latest updates and insights on Atai Beckley stock.
AtaiBeckley Inc. develops clinical-stage biotechnology programs for mental health conditions, with news centered on investigational therapies for treatment-resistant depression and social anxiety disorder. Recurring updates cover BPL-003, a mebufotenin benzoate nasal spray with FDA Breakthrough Therapy Designation for treatment-resistant depression; VLS-01, a DMT buccal film; and EMP-01, an oral R-MDMA program for social anxiety disorder.
Company announcements also address peer-reviewed clinical data, FDA interactions, patient-participant research practices, financial results, R&D spending, acquisition-related integration with Beckley Psytech, equity index inclusion, and capital runway disclosures. The news flow reflects a clinical-stage issuer whose operating updates are tied primarily to psychiatry-focused development programs, regulatory engagement, and financing capacity.
atai Life Sciences (NASDAQ: ATAI) announced its upcoming virtual R&D Day scheduled for October 25, 2022, aimed at reviewing its mental health pipeline. The event will showcase updates on various initiatives, including Phase 2a topline results for PCN-101 (R-ketamine) in treatment-resistant depression. Leadership will discuss the clinical and regulatory landscape, along with several programs including COMP360, VLS-01, RL-007, GRX-917, and KUR-101. This meeting emphasizes atai's commitment to addressing mental health disorders through innovative therapeutics.
atai Life Sciences has launched a Phase 1 proof-of-concept clinical trial for INB-01, an innovative intranasal drug-delivery technology. This trial aims to evaluate its safety, tolerability, and brain delivery efficacy. INB-01 could facilitate direct-to-brain delivery, enhancing patient compliance and minimizing systemic exposure. Topline results are anticipated in H1 2023. The technology has shown promising outcomes in animal studies, suggesting its potential effectiveness in humans. ATAI aims to transform mental health disorder treatment through innovative therapeutics.
atai Life Sciences announced positive initial results from the Phase 1 clinical trial of KUR-101, an oral formulation of deuterated mitragynine aimed at treating opioid use disorder (OUD). The trial showed KUR-101 is safe, well-tolerated, and produces dose-dependent analgesia without severe adverse effects. Topline results comparing KUR-101 to oxycodone are anticipated by the end of 2022. OUD affects approximately 3 million Americans, with high relapse rates. KUR-101 could offer a safer alternative in the growing global OUD market, projected to reach $4.81 billion by 2028.
atai has initiated a Phase 1 single-ascending dose (SAD) trial for its drug VLS-01, a synthetic form of DMT aimed at treating treatment-resistant depression (TRD). Topline results are expected in H1 2023. The trial will study the bioavailability of buccal versus IV formulations, safety, and tolerability. Approximately 100 million people globally suffer from TRD, highlighting the need for innovative treatments. The study incorporates atai's IDEA-1 digital therapeutic app to enhance the therapeutic experience.
atai Life Sciences (Nasdaq: ATAI) has announced its participation in several investor events in October 2022, including the Roth Inaugural Healthcare Opportunities Conference and Cantor Fitzgerald’s Neurology & Psychiatry Conference. The company aims to transform mental health treatment and will also host a virtual R&D Day on October 25, 2022. During the virtual event, key opinion leaders will discuss innovative approaches to treating mental health disorders. Archived webcasts will be accessible for up to 90 days on atai’s website.
atai Life Sciences has received regulatory and ethics approvals to start a Phase 1 trial for EMP-01, an MDMA derivative targeting PTSD. This trial will evaluate the safety and tolerability of EMP-01 in 32 healthy volunteers. The randomized, double-blind study aims to assess single-ascending doses and the usability of the IDEA-1 app. Current FDA-approved treatments for PTSD show limited efficacy, which emphasizes the need for new therapies. Topline results are expected in H2 2023.
atai Life Sciences (Nasdaq: ATAI), a clinical-stage biopharmaceutical company focused on mental health treatments, will participate in several investor conferences this September. Key events include the Citi’s BioPharma Conference on September 7, the H.C. Wainwright Global Investment Conference on September 13, the Cowen Neuropsychiatry Summit on September 19, and the Jefferies Psychedelics Summit on September 22. Presentations will be available via their website for up to 90 days.
atai Life Sciences reported a robust cash position of $312M as of June 30, 2022, boosted by a non-dilutive debt facility of up to $175M, extending its financial runway into 2025. The company has achieved several key milestones in its R&D pipeline, including the completion of a clinical phase study for PCN-101, database lock for GRX-917, and initiation of VLS-01. Expected clinical data readouts from eight programs are anticipated within the next 12 months, signaling potential significant developments in mental health treatments.
atai Life Sciences N.V. announced a term loan facility of up to $175 million with Hercules Capital to enhance its financial position in developing novel mental health treatments. This non-dilutive financing, combined with existing cash of $312 million, provides access to $487 million for advancing its drug pipeline. The funding structure includes flexible draw options and a 10.05% interest rate, maturing in 48 months. The CEO emphasized the strategic flexibility this provides for addressing unmet needs in neuropsychiatry.
atai Life Sciences, a clinical-stage biopharmaceutical company, will announce its second quarter 2022 financial results on August 15, 2022. The firm is focused on innovating treatments for mental health disorders, including depression and anxiety. A video interview with management will be available at 8:30 a.m. ET on the same day, with the recording to be accessible on their website. Founded in 2018, atai aims to accelerate drug development through a unique business model that integrates funding and regulatory expertise to tackle mental health challenges.